Make the Chinese Pay - with Tiny Biotech Stock

There's a simple, and maybe inevitable, way to make big money - at the expense of the Chinese government...  Dear Fellow Skeptic, There's a simple, and maybe inevitable, [way to make big money]( - at the expense of the Chinese government. In 2018, a small American biotech firm stunned the world when they showed they could "rewrite humans" to eliminate risk of disease. That's because this radical breakthrough will not just change how we treat diseases - It will determine which country is going to lead the [future of medicine for the next 50 years]( - the United States or China. The stakes couldn't be higher - National Defense Magazine says the breakthrough has "China is investing billions to make itself a world leader in this." The MIT Technology Review says the breakthrough has "world-shaping potential." The U.S. Director of National Security says the breakthrough has "far-reaching economic and national security implications." That's the real reason President Trump signed "Executive Order 13771" just ten days after taking office. For us to beat China, he had to reduce regulations at the FDA first. [Find out more here ]( The commercial value of the patent is astronomical. Investor's Business Daily estimates it's worth $75 billion. That means China, and the rest of the world, has to pay a license fee to use this new breakthrough. And a tiny American company owns the patent on this historic treatment. Its current market capitalization is just $1 billion. But analysts Keith S. thinks it will be worth twice what Facebook is worth or $1 Trillion. [That would be enough to turn every $1,000 into $1,000,000 (or more) ]( Sincerely, Josh K. Editor, Behind the Markets If you are you having trouble receiving your Stock Insiders subscription, you can ensure its arrival in your mailbox by [whitelisting Stock Insiders and si@stockinsiders.org.]( Stock Insiders (collectively, the “Company” or “we” used herein) bears no responsibility or control over the content of the advertisement and/or the product or service offered. This email is a paid advertisement. It is for a product or service that is not offered, recommended or endorsed by Stock Insiders and neither the company nor its affiliates bear responsibility or control over the content of the advertisement and the product or service offered. There is a very high degree of risk involved in trading. Past results are not indicative of future returns. Stock Insiders, all individuals and companies affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as advice. Information for any trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. By reading, downloading or otherwise consuming this content your information may be shared with our educational partners. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of Stock Insiders may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.  Your subscriber Id is: 39357a76f6d08b16239fd2ffa65e9c6f Proudly brought to you by: Stock Insiders of 3rd Fl, N&S Tower, 4 Selsdon Way, London, E14 9GL, UK In order to unsubscribe from this mailing list, please click [here](